BNP Paribas Exane Lowers Clorox (NYSE:CLX) Price Target to $97.00

Clorox (NYSE:CLX) had its price target reduced by analysts at BNP Paribas Exane from $128.00 to $97.00 in a research report issued to clients and investors on Tuesday,MarketScreener reports. The firm currently has a “neutral” rating on the stock. BNP Paribas Exane’s price target would suggest a potential upside of 5.32% from the stock’s current price.

CLX has been the topic of a number of other research reports. Jefferies Financial Group reduced their price objective on Clorox from $139.00 to $125.00 and set a “buy” rating on the stock in a research note on Monday, May 4th. UBS Group dropped their target price on Clorox from $110.00 to $96.00 and set a “neutral” rating on the stock in a report on Friday, May 1st. TD Cowen boosted their price target on Clorox from $98.00 to $111.00 and gave the stock a “hold” rating in a research report on Tuesday, March 31st. Barclays decreased their price target on Clorox from $102.00 to $85.00 and set an “underweight” rating for the company in a report on Friday, May 1st. Finally, Citigroup lowered their price objective on shares of Clorox from $110.00 to $97.00 and set a “neutral” rating for the company in a research report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating, twelve have given a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $103.73.

Clorox Trading Up 3.4%

Shares of CLX stock opened at $92.10 on Tuesday. The company has a quick ratio of 0.65, a current ratio of 0.84 and a debt-to-equity ratio of 27.03. Clorox has a fifty-two week low of $84.70 and a fifty-two week high of $136.69. The firm’s 50 day moving average price is $103.13 and its two-hundred day moving average price is $107.26. The stock has a market cap of $11.14 billion, a price-to-earnings ratio of 14.95, a price-to-earnings-growth ratio of 0.46 and a beta of 0.59.

Clorox (NYSE:CLX) last issued its earnings results on Thursday, April 30th. The company reported $1.64 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.09. The business had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.67 billion. Clorox had a net margin of 11.18% and a return on equity of 443.64%. The business’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.45 EPS. Clorox has set its FY 2026 guidance at 5.450-5.650 EPS. On average, analysts anticipate that Clorox will post 5.63 EPS for the current year.

Insider Activity

In related news, Director Pierre R. Breber acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was bought at an average cost of $85.82 per share, with a total value of $429,100.00. Following the acquisition, the director directly owned 18,000 shares in the company, valued at approximately $1,544,760. The trade was a 38.46% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.63% of the company’s stock.

Hedge Funds Weigh In On Clorox

A number of hedge funds have recently bought and sold shares of CLX. Cetera Investment Advisers raised its stake in Clorox by 44.5% during the first quarter. Cetera Investment Advisers now owns 105,704 shares of the company’s stock valued at $10,954,000 after buying an additional 32,539 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Clorox by 3.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 83,889 shares of the company’s stock worth $8,693,000 after acquiring an additional 2,439 shares in the last quarter. Oslo Pensjonsforsikring AS bought a new stake in shares of Clorox in the 1st quarter valued at approximately $158,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Clorox during the 1st quarter valued at approximately $86,000. Finally, Convergence Investment Partners LLC raised its position in shares of Clorox by 25.7% during the 1st quarter. Convergence Investment Partners LLC now owns 14,999 shares of the company’s stock valued at $1,554,000 after acquiring an additional 3,068 shares in the last quarter. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Clorox Company Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.